PRIMARY STUDY
Case Report: CBD Cigarettes for Harm Reduction and Adjunctive Therapy in a Patient With Schizophrenia and Substance Use Disorder
Key Findings: Cannabidiol (CBD) may be a therapeutic substitute in treating cannabis (THC cigarette) use disorder in a patient with schizophrenia and polysubstance abuse disorder.
Type of Study: Meta-analysis
Study Sample Size: 1
Study Result: Positive
Research Location(s): Germany, Switzerland
Year of Pub: 2021
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC)
Phytocannabinoid Source: Cannabis Flower derived
Chemotype: Chemotype III
Sub-Ratio: <7% CBD, <0.2% THC
Route of Administration: Inhalation
Citation: Meyer M, et al. Case Report: CBD Cigarettes for Harm Reduction and Adjunctive Therapy in a Patient With Schizophrenia and Substance Use Disorder. Front Psychiatry. 2021; 12:712110. doi: 10.3389/fpsyt.2021.712110
Authors: Meyer M, Walter M, Borgwardt S, Scheidegger A, Lang E, Köck P
